StreetInsider.com News Articles

Form 10-Q TherapeuticsMD, Inc. For: Jun 30

Tue, 11 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26905638.html

Form 10-Q TherapeuticsMD, Inc. For: Jun 30

Tue, 11 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26905638.html

Form 8-K TherapeuticsMD, Inc. For: Aug 11

Tue, 11 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260811/26905393.html

Form 8-K TherapeuticsMD, Inc. For: Aug 11

Tue, 11 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260811/26905393.html

TherapeuticsMD Announces Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 16:00:00 -0400

BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2026.

Second Quarter 2026 Financial Results

Net Income from Continuing Operations

Net income from continuing operations totaled $164 thousand, compared to net income of $545 thousand for the second quarter of 2025.

License Revenues from Continuing Operations

The Company recorded $864 thousand in license revenue, primarily from the Mayne License Agreement, for the second quarter of 2026, a decrease of $83 thousand, compared to $952 thousand in license revenue

TherapeuticsMD Announces Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 16:00:00 -0400

Second Quarter 2026 Financial Results

Net Income from Continuing Operations

Net income from continuing operations totaled $164 thousand, compared to net income of $545 thousand for the second quarter of 2025.

License Revenues from Continuing Operations

The Company recorded $864 thousand in license revenue, primarily from the Mayne License Agreement, for the second quarter of 2026, a decrease of $83 thousand, compared to $952 thousand in license revenue

TherapeuticsMD Announces Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 16:00:00 -0400

Second Quarter 2026 Financial Results

Net Income from Continuing Operations

Net income from continuing operations totaled $164 thousand, compared to net income of $545 thousand for the second quarter of 2025.

License Revenues from Continuing Operations

The Company recorded $864 thousand in license revenue, primarily from the Mayne License Agreement, for the second quarter of 2026, a decrease of $83 thousand, compared to $952 thousand in license revenue

TherapeuticsMD Announces Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 16:00:00 -0400

Second Quarter 2026 Financial Results

Net Income from Continuing Operations

Net income from continuing operations totaled $164 thousand, compared to net income of $545 thousand for the second quarter of 2025.

License Revenues from Continuing Operations

The Company recorded $864 thousand in license revenue, primarily from the Mayne License Agreement, for the second quarter of 2026, a decrease of $83 thousand, compared to $952 thousand in license revenue

Form SCHEDULE 13G/A TherapeuticsMD, Inc. Filed by: Baselake Partners, LP

Wed, 05 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260805/26875288.html

Form SCHEDULE 13G/A TherapeuticsMD, Inc. Filed by: Baselake Partners, LP

Wed, 05 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260805/26875288.html

Form 10-Q TherapeuticsMD, Inc. For: Mar 31

Tue, 12 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260512/26478167.html

Form 10-Q TherapeuticsMD, Inc. For: Mar 31

Tue, 12 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260512/26478167.html

Form 8-K TherapeuticsMD, Inc. For: May 02

Tue, 12 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260512/26477914.html

Form 8-K TherapeuticsMD, Inc. For: May 02

Tue, 12 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260512/26477914.html

TherapeuticsMD Announces First Quarter 2026 Financial Results

Tue, 12 May 2026 16:05:00 -0400

First Quarter 2026 Financial Results

Net Income (Loss) from Continuing Operations

Net income from continuing operations totaled $103 thousand, compared to a net loss of $636 thousand for the first quarter of 2025.

License Revenues from Continuing Operations

The Company recorded $724 thousand in license revenue, primarily from the Mayne License Agreement, an increase of $331 thousand, compared to $393 thousand in license revenue for the first quarter

TherapeuticsMD Announces First Quarter 2026 Financial Results

Tue, 12 May 2026 16:05:00 -0400

First Quarter 2026 Financial Results

Net Income (Loss) from Continuing Operations

Net income from continuing operations totaled $103 thousand, compared to a net loss of $636 thousand for the first quarter of 2025.

License Revenues from Continuing Operations

The Company recorded $724 thousand in license revenue, primarily from the Mayne License Agreement, an increase of $331 thousand, compared to $393 thousand in license revenue for the first quarter

TherapeuticsMD Announces First Quarter 2026 Financial Results

Tue, 12 May 2026 16:05:00 -0400

First Quarter 2026 Financial Results

Net Income (Loss) from Continuing Operations

Net income from continuing operations totaled $103 thousand, compared to a net loss of $636 thousand for the first quarter of 2025.

License Revenues from Continuing Operations

The Company recorded $724 thousand in license revenue, primarily from the Mayne License Agreement, an increase of $331 thousand, compared to $393 thousand in license revenue for the first quarter

TherapeuticsMD Announces First Quarter 2026 Financial Results

Tue, 12 May 2026 16:05:00 -0400

First Quarter 2026 Financial Results

Net Income (Loss) from Continuing Operations

Net income from continuing operations totaled $103 thousand, compared to a net loss of $636 thousand for the first quarter of 2025.

License Revenues from Continuing Operations

The Company recorded $724 thousand in license revenue, primarily from the Mayne License Agreement, an increase of $331 thousand, compared to $393 thousand in license revenue for the first quarter

Form SCHEDULE 13G TherapeuticsMD, Inc. Filed by: Baselake Partners, LP

Mon, 06 Apr 2026 21:31:00 -0400

si-local-file:///var/storage/secattach/20260406/26278000.html

Form SCHEDULE 13G TherapeuticsMD, Inc. Filed by: Baselake Partners, LP

Mon, 06 Apr 2026 21:31:00 -0400

si-local-file:///var/storage/secattach/20260406/26278000.html

Form NT 10-K TherapeuticsMD, Inc. For: Dec 31

Wed, 01 Apr 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260401/26254192.html

Form NT 10-K TherapeuticsMD, Inc. For: Dec 31

Wed, 01 Apr 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260401/26254192.html

Form 10-K/A TherapeuticsMD, Inc. For: Dec 31

Wed, 01 Apr 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260401/26254205.html

Form 10-K/A TherapeuticsMD, Inc. For: Dec 31

Wed, 01 Apr 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260401/26254205.html

Form 8-K TherapeuticsMD, Inc. For: Mar 30

Mon, 30 Mar 2026 17:57:00 -0400

si-local-file:///var/storage/secattach/20260330/26241937.html